Clinical Features Associated With Restless Legs Syndrome.

  • STATUS
    Recruiting
  • End date
    Sep 1, 2027
  • participants needed
    2000
  • sponsor
    University Hospital, Montpellier
Send
Updated on 15 September 2021
See if I qualify
depression
dopamine agonists
restless legs syndrome
neurological disorder
sleepiness

Summary

Restless legs syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs at night when at rest. RLS can lead to a sleep deprivation, increased falling risk, daytime sleepiness, depression and decreased quality of life. Dopamine agonists, alpha-2-delta ligands and opiates are key medications for RLS. The natural course of RLS is very heterogeneous with a risk of increasing the severity of symptoms over the years despite the use of drugs and recommended dosages. Many comorbidities can make RLS worse. Augmentation syndrome is the main complication of dopamine agonists. However, only a few studies have addressed the clinical, biological and pharmacological factors associated with the evolution of the severity of RLS. The objective of this study is to assess the evolution of RLS symptoms severity as function of RLS phenotype, comorbidities and RLS medication, in large cohort of members of the French RLS association and other European RLS association.

Description

In this study, the investigators want to study the clinical course of RLS in a population of RLS patients who are members of the RLS patient association, taking into account clinical and biological factors as well as the treatments taken for RLS.

Details
Condition Restless Legs Syndrome, nervous system disorder, Restless Leg Syndrome, Neurologic Disorders
Age 18years - 100years
Clinical Study IdentifierNCT05044520
SponsorUniversity Hospital, Montpellier
Last Modified on15 September 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Adults subjects
Restless legs syndrome diagnosis
Member of the restless legs syndrome association
French speaking
Able to understand the study
Signed written informed consent
Affiliated to social security

Exclusion Criteria

Vulnerable subject : subject deprived of liberty or protected by law (trusteeship, legal guardianship)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

depression
dopamine agonists
restless legs syndrome
neurological disorder
sleepiness

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.